Sweden, Aug. 23, 2022 /PRNewswire/
-- Immunovia today announced it will participate in Gilmartin
Group's Emerging Growth Company Showcase on August 31, 2022.
Philipp Mathieu, CEO and
President, and Jeff Borcherding, US
CEO, are scheduled to present on Wednesday,
August 31, 2022 at 9:00 am ET
(15:00 pm CET).
A live and archived webcast will be available on the 'Investors'
section of the Immunovia website at
For more information, please contact:
Karin Almqvist Liwendahl
+46 70 911 56 08
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information see:
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download:
SOURCE Immunovia AB